NanoViricides, Inc.

Release Summary

NanoViricides filed quarterly report. Company has over $46M cash in hand. Its anti-Ebola drug program, as well as FluCide™, DengueCide™ and other programs are progressing satisfactorily.

NanoViricides, Inc.